{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:45:05Z","timestamp":1767707105479,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"P-CREATE","award":["21cm0106106h0006"],"award-info":[{"award-number":["21cm0106106h0006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12185-022-03469-8","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T18:04:17Z","timestamp":1666634657000},"page":"78-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual inhibition of EZH1\/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1"],"prefix":"10.1007","volume":"117","author":[{"given":"Jumpei","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutsune","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Katsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8409-0407","authenticated-orcid":false,"given":"Issay","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukemia. Lancet. 2020;395:1146\u201362.","journal-title":"Lancet"},{"key":"3469_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","volume":"12","author":"B Li","year":"2019","unstructured":"Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol. 2019;12:118.","journal-title":"J Hematol Oncol"},{"key":"3469_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1258\/ebm.2012.012075","volume":"237","author":"J Chen","year":"2012","unstructured":"Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med. 2012;237:1110\u20136.","journal-title":"Exp Biol Med"},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","volume":"126","author":"M Mochizuki-Kashio","year":"2015","unstructured":"Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood. 2015;126:1172\u201383.","journal-title":"Blood"},{"key":"3469_CR5","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1073\/pnas.1202258109","volume":"109","author":"T Neff","year":"2012","unstructured":"Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci USA. 2012;109:5028\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3469_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nchembio.1331","volume":"9","author":"W Kim","year":"2013","unstructured":"Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9:643\u201350.","journal-title":"Nat Chem Biol"},{"key":"3469_CR7","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/cas.13326","volume":"108","author":"D Honma","year":"2017","unstructured":"Honma D, Kanno O, Watanabe J, Kinoshita J, Hirasawa M, Nosaka E, et al. Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017;108:2069\u201378.","journal-title":"Cancer Sci"},{"key":"3469_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2017.300","volume":"32","author":"S Fujita","year":"2018","unstructured":"Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, et al. Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia. 2018;32:855\u201364.","journal-title":"Leukemia"},{"key":"3469_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/cas.13840","volume":"110","author":"M Nakagawa","year":"2019","unstructured":"Nakagawa M, Fujita S, Katsumoto T, Yamagata K, Ogawara Y, Hattori A, et al. Dual inhibition of enhancer of zeste homolog 1\/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. Cancer Sci. 2019;110:194\u2013208.","journal-title":"Cancer Sci"},{"key":"3469_CR10","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29:2321\u201337.","journal-title":"Cell Rep"},{"key":"3469_CR11","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1111\/cas.14905","volume":"112","author":"Y Kagiyama","year":"2021","unstructured":"Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, et al. CDKN1C-mediated growth inhibition by an EZH1\/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Cancer Sci. 2021;112:2314\u201324.","journal-title":"Cancer Sci"},{"key":"3469_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0145-2126(02)00227-8","volume":"27","author":"\u00d8 Bruserud","year":"2003","unstructured":"Bruserud \u00d8, Glenjen N, Ryningen A, Ulvestad E. In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines. Leuk Res. 2003;27:455\u201364.","journal-title":"Leuk Res"},{"key":"3469_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108\u201312.","journal-title":"Nature"},{"key":"3469_CR14","doi-asserted-by":"publisher","first-page":"21360","DOI":"10.1073\/pnas.1210371110","volume":"109","author":"W Qi","year":"2012","unstructured":"Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA. 2012;109:21360\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18:298\u2013301.","journal-title":"Nat Med"},{"key":"3469_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-19-0789","volume":"10","author":"TE Le\u00f3n","year":"2020","unstructured":"Le\u00f3n TE, Rapoz-D\u2019Silva T, Bertoli C, Rahman S, Magnussen M, Philip B, et al. EZH2-deficient T-cell acute lymphoblastic leukemia is sensitized to CHK1 inhibition through enhanced replication stress. Cancer Dsicov. 2020;10:998\u20131017.","journal-title":"Cancer Dsicov"},{"key":"3469_CR17","first-page":"3","volume":"47","author":"RE Brown","year":"2017","unstructured":"Brown RE, Konopka KE, Weerasinghe P, Jaitly V, Dasgupta A, McGuire MF, et al. Morphoproteomics identifies SIRT1 and EZH2 pathways as commonalities in B-cell acute lymphoblastic leukemia: pathogenetic implications and opportunities for therapeutic intervention. Ann Clin Lab Sci. 2017;47:3\u20139.","journal-title":"Ann Clin Lab Sci"},{"key":"3469_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346\u201357.","journal-title":"Blood"},{"key":"3469_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s12185-015-1858-1","volume":"102","author":"H Li","year":"2015","unstructured":"Li H, Kong X, Cui G, Ren C, Fan S, Sun L, et al. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR\/p70S6K pathway in acute lymphoblastic leukemia cells. Int J Hematol. 2015;102:558\u201368.","journal-title":"Int J Hematol"},{"key":"3469_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","volume":"51","author":"W Zhang","year":"2019","unstructured":"Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med. 2019;51:28\u201340.","journal-title":"Ann Med"},{"key":"3469_CR21","volume":"2","author":"D Ragusa","year":"2019","unstructured":"Ragusa D, Makarov EM, Britten O, Moralli D, Green CM, Tosi S. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features. Cancer Rep. 2019;2: e1207.","journal-title":"Cancer Rep"},{"key":"3469_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fgene.2013.00080","volume":"4","author":"J Shahbazi","year":"2013","unstructured":"Shahbazi J, Lock R, Liu T. Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis. Front Genet. 2013;4:80.","journal-title":"Front Genet"},{"key":"3469_CR23","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1038\/sj.onc.1208951","volume":"24","author":"R Tomasini","year":"2005","unstructured":"Tomasini R, Seux M, Nowak J, Bontemps C, Carrier A, Dagorn JC, et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene. 2005;24:8093\u2013104.","journal-title":"Oncogene"},{"key":"3469_CR24","first-page":"3729","volume":"18","author":"W Ye","year":"2019","unstructured":"Ye W, Liang F, Ying C, Zhang M, Feng D, Jiang X, et al. Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP1. Exp Ther Med. 2019;18:3729\u201336.","journal-title":"Exp Ther Med"},{"key":"3469_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3324\/haematol.2018.199364","volume":"105","author":"S Demir","year":"2020","unstructured":"Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:170\u201381.","journal-title":"Haematologica"},{"key":"3469_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3469_CR27","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","volume":"35","author":"K Perica","year":"2021","unstructured":"Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021;35:3268\u201371.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03469-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:11:31Z","timestamp":1672841491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03469-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}